Literature DB >> 22308517

Treatment of non-small cell lung cancer in the older patient.

Apar Kishor Ganti1, Mollie deShazo, Alva B Weir, Arti Hurria.   

Abstract

Lung cancer is a disease of the elderly, with a median age at diagnosis of 70 years. However, there is a dearth of good quality evidence to guide treatment in this population and most of the data are extrapolated from younger patients. Current research is directed toward establishing simplified instruments to quantify fitness of older patients for various forms of therapy. Although current evidence suggests that outcomes after standard therapy are similar to those seen in younger patients, older patients have an increased incidence of adverse events. Until better predictive markers are available to guide treatment, therapy should be individualized using available instruments, including a comprehensive geriatric assessment. If an older patient is deemed to be fit, it is reasonable to use the treatment options recommended for younger individuals. This article summarizes the available data on the treatment of non-small cell lung cancer in the older patient.

Entities:  

Mesh:

Year:  2012        PMID: 22308517     DOI: 10.6004/jnccn.2012.0021

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  7 in total

1.  Treatment Toxicity in Elderly Patients With Advanced Non-Small Cell Lung Cancer.

Authors:  Minal S Kale; Grace Mhango; Jorge E Gomez; Keith Sigel; Cardinale B Smith; Marcelo Bonomi; Juan P Wisnivesky
Journal:  Am J Clin Oncol       Date:  2017-10       Impact factor: 2.339

2.  Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study.

Authors:  Melisa L Wong; Timothy L McMurry; George J Stukenborg; Amanda B Francescatti; Carla Amato-Martz; Jessica R Schumacher; George J Chang; Caprice C Greenberg; David P Winchester; Daniel P McKellar; Louise C Walter; Benjamin D Kozower
Journal:  Lung Cancer       Date:  2016-11-09       Impact factor: 5.705

3.  When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.

Authors:  A Nacci; N Calvani; P Rizzo; P Fedele; L Orlando; P Schiavone; M Cinefra; A Marino; F Sponziello; M D'Amico; S Cinieri
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

4.  Therapeutic options in older patients with metastatic non-small cell lung cancer.

Authors:  Elisabeth Quoix
Journal:  Ther Adv Med Oncol       Date:  2012-09       Impact factor: 8.168

5.  Surviving with lung cancer: medication-taking and oral targeted therapy.

Authors:  Karen E Wickersham; Mary Beth Happ; Catherine M Bender; Sandra J Engberg; Ahmad Tarhini; Judith A Erlen
Journal:  Geriatr Nurs       Date:  2014 Mar-Apr       Impact factor: 2.361

6.  Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma.

Authors:  Sixian Chen; Aizhen Fu; Yuan Lu; Wei Lu; Yongfeng Chen; Shuiqiang Hong; Suli Zhou; Tianmin Xiang; Zhenzhen Zhang; Yongguang Cai
Journal:  BMC Genomics       Date:  2022-01-15       Impact factor: 3.969

7.  Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.

Authors:  Xiaoyu Zhai; Lu Yang; Sipeng Chen; Qiwen Zheng; Ziping Wang
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.